A20は心臓内で動的に調節され,高縮性反応を抑制する
Stuart A Cook1, Mikhail S Novikov, Youngkeun Ahn
1Program in Cardiovascular Gene Therapy, Cardiovascular Research Centre and Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Charlestown, Mass 02129, USA.
Circulation
|August 6, 2003
まとめ
A20タンパク質の発現は,心臓のストレスとともに増加し,NF-kappaBシグナル伝達を阻害することによって,心筋縮を抑制します. この保護効果は,心筋細胞アポトーシスを増加させることなく発生します.
科学分野:
- 心血管生物学 心血管生物学
- 分子心臓病学 分子心臓病学
- 細胞シグナル伝達 細胞信号伝達
背景:
- 核因子 (NF) -kappaBシグナル伝達は,心筋細胞高縮と関連しています.
- A20は,NF-kappaBシグナル伝達の阻害剤として知られています.
研究 の 目的:
- A20の心臓の調節と生物学的活動を調査する.
- 心臓におけるNF-kappaBシグナル伝達を阻害するA20の役割を決定する.
主な方法:
- マウスにおける大動脈帯膜は,A20表現を評価する.
- 培養された新生児心筋細胞をフェニレフリンまたはエンドセリン-1. 1で刺激する.
- アデノウイルスのベクター媒介による遺伝子転送により,心筋細胞でA20またはdNIKKβを発現する.
主要な成果:
- A20 mRNAは,マウスの前大動脈帯形成後に著しく上昇し,NF-kappaBの活性化と相関しています.
- A20発現は,NF-kappaBの活性化に並行して,高濃縮剤で刺激された心筋細胞で増加した.
- A20発現は,NF-kappaBシグナル伝達と,アポトーシスを増加させることなく,心筋細胞における高縮反応を阻害した.
結論:
- A20は,心臓の急性生体力学的ストレスによって動的に調節されます.
- A20は,NF-kappaBシグナル伝達を阻害することによって,心筋縮を弱める.
- A20は,ストレス中に心筋細胞をアポトーシスから保護します.
関連する概念動画
Pathophysiology of Cardiac Performance
2.2K
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
2.2K
Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Antianginal Drugs: Nitrates and β-Blockers
1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Regulation of Heart Rates
6.0K
The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
6.0K


